Patent Licensing and Technology Transfer Toolkit

By Casey Scott McKay · 2025-09-04

A patent licence is a bounded permission not to be sued, and the value in one lies entirely in the boundaries. This toolkit runs a licence from the decision to license through negotiation, administration, and termination, and routes each stage to the Marksy documents that do the work. It explains what exclusivity actually conveys and why an exclusive licensee may or may not be able to sue alone, why the royalty base matters more than the rate, how sublicensing and have-made rights determine whether a licence works in a real supply chain, and what improvements and grant-back provisions do to a licensor's future. It covers diligence obligations, minimum payments, audit rights, termination, and the bankruptcy risk that surprises licensees. It closes with university technology transfer, know-how, and the reading path, the authorities table, and the forms.

IP and Technology > IP and IT in Corporate Transactions | Toolkit | Published 4 September 2025 - Updated 22 April 2026 | Casey Scott McKay - marksy.us

Summary. A patent licence is a bounded permission not to be sued, and the value in one lies entirely in the boundaries. This toolkit runs a licence from the decision to license through negotiation, administration, and termination, and routes each stage to the Marksy documents that do the work. It explains what exclusivity actually conveys and why an exclusive licensee may or may not be able to sue alone, why the royalty base matters more than the rate, how sublicensing and have-made rights determine whether a licence works in a real supply chain, and what improvements and grant-back provisions do to a licensor's future. It covers diligence obligations, minimum payments, audit rights, termination, and the bankruptcy risk that surprises licensees. It closes with university technology transfer, know-how, and the reading path, the authorities table, and the forms.

Keywords: patent license · exclusive versus non-exclusive · field of use · territory and term · running royalty · lump sum · minimum annual payment · royalty base · sublicensing · have made rights · improvements and grant back · diligence obligations · audit rights · termination · bankruptcy protection · enforcement standing · marking obligation · university technology transfer · cross licensing · know how transfer

Start Here

Weatherly Materials has four licensing conversations running at once, handled by four different people, and none of them has the same idea of what a licence is.

The business development team is negotiating an exclusive licence out to a manufacturer in a field the company does not serve, and has agreed to "exclusive worldwide rights" without defining the field.

The engineering team is taking a licence in from a university, and the term sheet contains diligence milestones nobody has costed.

Procurement is negotiating a component supply agreement whose licence grant does not include have-made rights, which matters because the company outsources assembly.

And a competitor has offered a cross-licence covering both portfolios, which the chief executive regards as free and which will bind the company's future development.

Four transactions, one instrument, and a common misunderstanding: that a licence is a permission. It is a bounded permission, and every boundary is a term somebody has to write.

This toolkit answers three questions.

What is being licensed, and to whom? Patents by number, in a field, in a territory, for a term, to a named party and whichever of its affiliates and contractors it needs.
What is being paid, and on what? The base determines more than the rate, and the payment structure determines whether the deal survives a bad year.
What happens when things change? Improvements, sublicensing, assignment, breach, insolvency, and expiry. A licence is a long relationship and most of its terms address the future.

If you read only one thing, read Assignment vs. License. The distinction between transferring ownership and granting permission organizes everything else, and it is confused constantly.

What a Licence Actually Is

A covenant not to sue, bounded. The licensor agrees not to assert specified patents against specified conduct by specified parties. Everything else in the document defines those three.

It conveys no ownership. 35 U.S.C. § 261 governs assignment; a licence is not one, and the distinction determines who may enforce, who may sublicense, and what happens on insolvency.

It does not guarantee freedom to operate. A licence under one party's patents says nothing about third parties, which means a licensee still needs its own clearance. See Freedom-to-Operate and Patent Clearance Toolkit.

It does not warrant validity. A licensee may generally challenge validity notwithstanding the licence, and licences that purport to prohibit it are of doubtful enforceability. What a licence can do is provide that a challenge triggers termination or a rate increase.

It is territorial and temporal. Patents are national and they expire, and a royalty extending beyond expiry of the last licensed patent is unenforceable as to the post-expiry period.

Exclusive, Sole, and Non-Exclusive

Non-exclusive. The licensor may license others and may practice itself. The most common form, the cheapest, and it confers no standing to sue.

Sole. The licensor will not license others but retains the right to practice itself. A middle position that is frequently what parties mean when they say exclusive.

Exclusive. Nobody else, including the licensor, may practice within the granted scope. The licensor's retained rights, if any, must be stated expressly.

Why the distinction matters for enforcement. An exclusive licensee holding all substantial rights may sue in its own name. One holding less must join the patentee, and a non-exclusive licensee has no standing at all. 35 U.S.C. § 281.

What "all substantial rights" turns on. The scope of exclusivity, the right to sue, the right to sublicense, the licensor's retained approval rights, the duration relative to the patent term, and who controls prosecution and maintenance. A licence styled exclusive that reserves enforcement to the licensor does not convey all substantial rights.

Exclusive within a field. The workable middle for most transactions, and it requires the field to be defined with precision — by application, by market, by product category, or by technical parameter. Fields defined loosely produce disputes when a market grows into the gap.

Scope: The Four Boundaries

Patents. By number, including the applications and any continuations, divisionals, and foreign counterparts. A licence to "the Licensor's patents relating to X" is a licence to whatever a court later decides that means.

Field of use. Application, market, or product category. Precisely enough that a new product can be classified without argument.

Territory. Country by country, matched to where patents actually exist. A worldwide licence under a portfolio filed in three countries is a licence in three countries.

Term. Through expiry of the last licensed patent, or a stated period, with what happens at the end stated.

Permitted acts. Make, have made, use, sell, offer to sell, and import. Each is a separate act under 35 U.S.C. § 271 and each must be granted expressly.

Have-made rights. The right to have the product made by a contract manufacturer. Without it, a licensee that outsources manufacturing has a licence its manufacturer cannot use, which is Weatherly's procurement problem.

Affiliates. Whether the grant extends to subsidiaries, and what happens when an affiliate is sold or acquired.

Downstream. Whether customers and distributors are covered. A licence to a manufacturer that does not extend downstream leaves the channel exposed, though exhaustion on an authorized sale addresses much of this.

Payment Structures

Running royalty. A percentage or a per-unit amount on covered sales. Aligns payment with success, requires reporting and audit machinery, and requires a base definition that will bear scrutiny.

Lump sum. One payment, or a schedule. Simple, certain, and it removes the reporting burden. It also removes the upside for a licensor and the downside protection for a licensee.

Paid-up. A lump sum covering the full term.

Hybrid. An upfront payment plus a reduced running royalty, which is the most common structure in practice.

Milestone payments, common where the licensed technology requires development before it generates revenue.

Minimum annual payments. The provision that matters most to a licensor granting exclusivity, because it prevents a licensee from taking a field and doing nothing with it.

The royalty base. More consequential than the rate. A rate on the end product produces a very different number from the same rate on the component that practices the claim, and the apportionment principle points toward the smallest salable unit. This is the same argument that runs in damages litigation and it is worth understanding before negotiating. See What a Patent Is Worth in Court.

Stacking provisions. Where the licensee must pay royalties to others on the same product, a stacking clause reduces this royalty proportionally. Licensors resist and licensees in crowded fields need it.

Post-expiry royalties. A royalty obligation extending past the expiry of the last licensed patent is unenforceable as to that period, and the standard fix is a stepped-down rate attributable to know-how.

Reporting, Audit, and Administration

Reports. Quarterly or semi-annual, stating units, covered sales, deductions, and the royalty computed. A report with a number and no computation is unauditable.

Deductions. Returns, allowances, shipping, insurance, and taxes are commonly deducted from the base, and each should be enumerated because the list is where the base erodes.

Audit rights. An independent accountant, on notice, at defined intervals, with the licensor paying unless the audit reveals an underpayment above a threshold. The threshold and the fee-shifting are what make the right usable.

Records retention, long enough to support an audit reaching back several periods.

Late payment interest, and a materiality threshold for breach.

Currency and withholding, for cross-border arrangements, including which party bears withholding tax and whether payments are grossed up.

Why administration matters. A running royalty licence that nobody administers becomes a lump sum licence at whatever the licensee chooses to report. The most common failure in licensing practice is a licensor that never audits.

Improvements and Grant-Backs

Define improvement precisely. Improvements to the licensed technology, improvements to the licensee's own technology, and improvements made jointly are three different things.

Whether improvements are included in the licence going forward. A licensee taking a licence to a technology in active development needs them; a licensor may not want to grant them for free.

Grant-backs. A licence back to the licensor covering the licensee's improvements. Reasonable in narrow form and problematic in broad form, both commercially and under competition principles. Scope, exclusivity, field, and duration should each be stated. 15 U.S.C. § 1.

Assignment of improvements is more aggressive than a licence back and is resisted accordingly.

Post-termination. Whether an improvement licence survives termination, and in which direction.

Enforcement and Standing

Who may sue. The patentee always. An exclusive licensee with all substantial rights may sue alone; one with less must join the patentee; a non-exclusive licensee may not sue.

Address it expressly. Who controls an action, who pays, who selects counsel, how recoveries are shared, and whether the other party must join at request and expense.

The joinder obligation is essential where the licensee will enforce, because a patentee who declines to join can make the patent unenforceable.

Marking. A licensee selling a patented article must mark, or the patentee's damages are limited to the period after actual notice. 35 U.S.C. § 287. A licensor that does not require licensee marking has given away years of its own damages, and this is the most commonly omitted provision in the entire instrument.

Notice of infringement. An obligation on each party to notify the other of suspected infringement.

Settlement authority, because a settlement granting a licence to an accused infringer affects the other party.

Challenge provisions. What happens if the licensee challenges validity — termination, a rate increase, or nothing.

Termination and Insolvency

Termination for breach, with a cure period, and with the licensor's remedy for non-payment separated from other breaches.

Termination for convenience by the licensee, which is common where minimum payments apply, and which the licensor should condition on notice.

What survives. Confidentiality, accrued payment obligations, sublicences granted before termination, and any improvement licences.

Sublicences on termination. Whether a sublicensee's rights survive the termination of the head licence. A sublicensee that loses its rights because its licensor breached has no remedy against the licensor it never dealt with, and the fix is a direct undertaking from the head licensor.

Insolvency of the licensor. Where the licensor's estate rejects the licence, 11 U.S.C. § 365(n) permits a licensee of intellectual property to elect to retain its rights and continue paying royalties. The provision is a genuine protection for patent licensees and its coverage of trademarks is a separate and long-contested question.

Insolvency of the licensee. The licensor's remedies, and whether the licence may be assumed and assigned over the licensor's objection.

Change of control. Whether either party may terminate on a change of control of the other, which matters most where the counterparty could be acquired by a competitor.

University Technology Transfer

The institution's policy governs and is largely non-negotiable: ownership of what its people invent, publication rights, limited indemnities, and reserved rights for research and teaching.

Federal funding attaches obligations. 35 U.S.C. § 200 states the policy; 35 U.S.C. § 202 permits the institution to elect title subject to disclosure, a government licence, and preference for domestic manufacture; 35 U.S.C. § 203 supplies march-in rights.

What this means for an exclusive licensee. The exclusivity is subject to the government's licence and to the institution's reserved research rights, and it cannot be otherwise.

Diligence milestones. Institutions require them, because an exclusive licence that sits unused defeats the purpose of the transfer. They should be costed before they are agreed — Weatherly's engineering team has not done this — and they should include a renegotiation mechanism for milestones that become infeasible.

Publication. The institution will publish. A review window and a filing delay is the accommodation, and an indefinite embargo is not available.

Equity and sponsored research frequently accompany the licence, and each carries its own terms.

Know-how. The patents are rarely enough. A technology transfer that does not include the inventors' time, the protocols, and the tacit knowledge frequently fails, and the transfer plan matters more than the licence terms.

Cross-Licences

What they are. Each party licenses the other under its portfolio, usually to resolve mutual exposure rather than to transfer technology.

Why they are not free. A cross-licence gives away the company's exclusion rights against a specific competitor, permanently or for a term, in exchange for the same. It should be valued on both sides rather than treated as a mutual convenience.

Scope is everything. Current patents only, or future ones. All fields, or defined ones. Existing products, or future ones. A broadly scoped cross-licence executed casually forecloses assertion against the counterparty for a generation.

Balancing payments where the portfolios are unequal.

Capture periods, limiting which future patents are included.

Change of control, because a cross-licence that travels to an acquirer extends the grant to a company the client never evaluated.

The chief executive's instinct that it is free is the recurring problem, and the answer is to price both sides and to bound the scope.

Weatherly's Four Transactions, Answered

The undefined exclusive. "Exclusive worldwide rights" with no field defined grants everything, everywhere, including the fields the company does serve. Define the field by application and product category, define the territory against the countries where patents actually exist, retain rights to practice and to license outside the field, and add minimum annual payments so the field is not taken and left idle.

The university term sheet. Cost the diligence milestones before agreeing to them, and build in a renegotiation mechanism. Confirm the funding source, because a government licence and march-in rights attach to federally supported inventions and constrain the exclusivity. And plan the know-how transfer, because the patents alone will not work.

The missing have-made rights. A licence permitting the company to make and sell but not to have made does not permit contract manufacture. Add it expressly, and check the affiliate definition while you are there.

The cross-licence. Not free. Value both portfolios, bound the capture period, limit the fields, and add a change-of-control provision. A broad cross-licence with a competitor is one of the most consequential documents a technology company ever signs and it is routinely signed at the wrong level.

Negotiating a Licence Out

The licensor's positions, in the order they matter.

Define the field narrowly and reserve everything else. The single most valuable position available. An exclusive licence granted broadly cannot be walked back, and a licensee that grows into an adjacent market on an undefined field has taken something nobody sold it.

Insist on minimum annual payments wherever exclusivity is granted. They convert an idle field into either revenue or a reversion, and they are the licensor's only protection against a licensee that acquires a field defensively.

Require diligence obligations with defined milestones and a reversion or conversion to non-exclusive on failure.

Take the marking obligation. 35 U.S.C. § 287. A licensee that does not mark limits the licensor's own damages against third parties, and this is the most commonly omitted provision in licences drafted by licensors.

Keep prosecution and maintenance control, or at minimum a step-in right if the licensee stops paying.

Keep enforcement control unless the licence is genuinely a transfer, and if the licensee controls, require joinder, consultation, and a share of recoveries.

Constrain sublicensing. Consent, or defined categories, with sublicensees bound to the same obligations and with the licensor able to reach them directly if the head licence ends.

Constrain assignment, particularly to competitors, and add a change-of-control provision.

Build in audit rights with teeth, including fee-shifting above a threshold, and then actually exercise them. A running royalty nobody audits becomes whatever the licensee reports.

Address the challenge scenario. A licensee that challenges validity may do so, and the licence can provide for termination or a rate increase.

Negotiating a Licence In

The licensee's positions, in the order they matter.

Get the acts you actually need. Make, have made, use, sell, offer to sell, and import. Have-made rights specifically, because outsourced manufacture is the norm and the omission is the norm too.

Get affiliates and the downstream channel covered. Subsidiaries, contract manufacturers, distributors, and customers. A licence that stops at the licensee leaves the channel exposed.

Fix the royalty base low and defensibly, at the component that practices the claim rather than at the end product. The base moves the number more than the rate, and the argument is the same apportionment argument that runs in damages cases.

Get a stacking provision where the field is crowded.

Get the term right. Through expiry of the last licensed patent, with a step-down for any know-how component so the obligation does not extend past patent expiry unenforceably.

Get improvements, at least those made during the term, at least on a non-exclusive basis.

Limit the grant-back to improvements to the licensed technology, non-exclusive, in the licensor's field only.

Get a covenant not to sue affiliates and customers, which is broader than a licence and cheaper to obtain than it sounds.

Get the bankruptcy protection acknowledged. 11 U.S.C. § 365 supplies an election to retain rights on rejection, and confirming its application in the document costs nothing.

Do not accept a validity-challenge prohibition, and understand that a termination-on-challenge provision is the ordinary compromise.

Confirm the licensor owns what it is licensing. Chain of title, assignments executed, and no conflicting grants. 35 U.S.C. § 261.

Setting the Rate

The rate conversation is a valuation conversation and the inputs are the same ones that appear in damages litigation.

Comparable licences are the strongest evidence in both directions, and they carry the familiar difficulties: portfolio licences covering many patents, licences negotiated under litigation pressure, cross-licences with no cash rate, and licences reflecting different volumes and fields.

The design-around cost sets the ceiling. A licensee that could avoid the patents for a modest engineering change will not pay more than that change costs, plus the delay. Both sides should know this number before negotiating, and the licensor frequently does not.

The value of the contribution sets the floor. What does the technology add over the next best alternative, in cost saved, price supported, or volume enabled?

Industry norms are a weak input, invoked constantly, and worth checking only where the field genuinely has established practice.

Rules of thumb are not evidence. The twenty-five percent rule and an even split of incremental profit are rejected in litigation and they persist in negotiation. They can serve as a starting anchor and they will not survive scrutiny.

Structure can bridge a gap on rate. Where the parties disagree about how successful the product will be, a lower rate with a higher minimum, or a rate that steps down after a volume threshold, prices the disagreement rather than arguing it.

Milestones bridge development risk. Where the technology needs work before it earns, payments tied to technical and commercial milestones align the parties.

Exclusivity is priced separately from the rate, and a licensee wanting exclusivity should expect to pay for it in minimums rather than in a higher percentage.

Administering the Licence

A licence is a decade-long relationship and most of them are filed after signature and never looked at again.

Calendar the obligations. Reporting dates, minimum payment dates, milestone deadlines, audit windows, notice periods, and renewal or termination dates.

Read the first report carefully. The base computation, the deductions taken, and the units reported. Errors and misunderstandings surface in the first report and they compound if uncorrected.

Audit on a schedule, not on suspicion. An audit conducted only when the licensor is unhappy reads as an attack; one conducted every third year as a matter of course reads as administration.

Track the patents. A licence covering patents that lapse for maintenance fees is a licence covering less each year, and the party paying the fees should be identified.

Track the products. A licensee's product line evolves, and whether new products fall inside the field is a question somebody should answer as it arises rather than at audit.

Track sublicences, because a licensor with no visibility into sublicensing has no visibility into its own revenue base.

Revisit at each milestone. A licence that has become a poor fit for both parties is frequently renegotiable, and neither side raises it.

Record it in the portfolio inventory. An encumbrance the company cannot describe is an encumbrance that surfaces in diligence as a problem.

Know-How, and Why Patents Alone Fail

Technology transfer fails on know-how more often than on terms, and a licence that transfers only patents transfers a right to be free of one company's assertions rather than an ability to build anything.

What know-how is. The protocols, the parameters, the failure modes, the fixtures, the process settings, and the accumulated judgment of the people who made the thing work. Protected as a trade secret where the elements are met. 18 U.S.C. § 1839.

Why the patents do not contain it. A specification must enable a skilled artisan to practice the claimed invention under 35 U.S.C. § 112, which is a considerably lower bar than commercial viability. Everything between enablement and a working production line is know-how.

What a transfer plan contains. Documentation, defined and scheduled. Access to named individuals for a stated number of hours. On-site support during a defined commissioning period. Sample materials and fixtures. Training. And a completion test — some objective demonstration that the transferee can operate independently.

Payment for know-how is separable, which matters because it permits a royalty structure that continues past patent expiry attributable to the know-how rather than to the patents.

Confidentiality obligations govern it, and they should carry a trade secret carve-out to the survival period rather than a flat term.

Reverse know-how flows too. A licensee that improves the process learns things the licensor wants, and the improvement and grant-back provisions are where that is handled.

The recurring failure. A licence executed, patents assigned or licensed, and no plan for the people. Six months later the licensee cannot make the product, blames the technology, and the licensor blames the licensee. Both are wrong; nobody transferred the know-how.

Ten Provisions That Decide Disputes

Across licences of every kind, the same ten provisions produce nearly all of the litigation.

The field definition, where a market grew into an ambiguity nobody noticed at signature.

The royalty base, where "net sales of Licensed Products" turns out to mean two different things to two parties.

The deductions, where a base erodes by a third through allowances nobody enumerated.

Have-made rights, where a licensee outsourced manufacture under a licence that did not permit it.

Affiliate coverage, where a subsidiary acquired after signature turns out to be outside the grant.

Sublicensing, where a licensee granted rights the head licence did not permit, or where sublicensees lost their rights when the head licence terminated.

Improvements, where a party developed something and the other believes the licence covers it.

Enforcement control, where an infringer appeared and neither party could sue alone.

Termination survival, where a licence ended and nobody wrote down which grants continued.

Change of control, where a counterparty was acquired by a competitor and the licence travelled with it.

What they share. Each is a drafting question answerable in a sentence at signature and answerable only by litigation afterward, and each is skipped because the parties are focused on the rate. The rate is the term that gets negotiated and these are the terms that get disputed.

When Not to License

Three situations where the answer is no, and saying so is the advice.

Where exclusivity is being given away for a payment. An exclusive licence in a field the licensor may later want is a sale of that field, priced as a licence. If the company might enter the market in five years, a non-exclusive licence or a field defined more narrowly is the right instrument.

Where the licensee is a future competitor. A licence that teaches a company how to compete, in exchange for a royalty stream that ends when the patents do, is a trade most licensors would decline if it were framed that way.

Where the counterparty cannot perform. An exclusive licence to a party without the capital, the channel, or the manufacturing to commercialize sterilizes the technology for the term. Diligence milestones and minimums are the mitigation, and declining is sometimes better.

And one situation where licensing is clearly right. Where the company will not practice the technology itself, where the field is one it will never enter, and where the alternative is a patent maintained at cost and used for nothing. Most portfolios contain several of these, and identifying them is exactly what the inventory and competitor mapping in the portfolio toolkit exist to produce.

A Suggested Reading Path

If you are licensing out:

If you are licensing in:

If a collaboration is involved:

Primary Authorities

| Authority | Proposition | |---|---| | 35 U.S.C. § 261 | Assignment; the licence distinction | | 35 U.S.C. § 262 | Joint owners; independent licensing | | 35 U.S.C. § 271 | The acts a licence must permit | | 35 U.S.C. § 281 | Civil action; who may sue | | 35 U.S.C. § 282 | Presumption of validity | | 35 U.S.C. § 284 | Damages; the royalty benchmark | | 35 U.S.C. § 287 | Marking; the licensee obligation | | 35 U.S.C. § 154 | Term; the end of the royalty | | 35 U.S.C. § 200 | Federal funding policy | | 35 U.S.C. § 202 | Election of title; government licence | | 35 U.S.C. § 203 | March-in rights | | 35 U.S.C. § 41 | Maintenance; who pays | | 11 U.S.C. § 365 | Executory contracts; licensee protection | | 15 U.S.C. § 1 | Restraints; grant-backs and cross-licences | | 15 U.S.C. § 2 | Monopolization; refusal to license | | 18 U.S.C. § 1839 | Trade secret; the know-how component |

Forms and Templates

The License Agreement Template is the working document, and the provisions worth the most attention are the ones this toolkit dwells on: the four boundaries, the have-made and affiliate definitions, the royalty base, the marking obligation, the enforcement joinder, and what survives termination. The Assignment Agreement Template is the alternative instrument where the transaction is actually a transfer, and choosing the wrong one produces years of confusion about who may enforce. The Portfolio Inventory Template is where granted licences and encumbrances belong, because a portfolio whose licence obligations are not recorded is a portfolio nobody can accurately represent in a transaction. The Cease and Desist Template marks the other route: licensing conversations frequently begin with an assertion, and how the first letter is framed shapes the negotiation that follows.

Related Toolkits and Checklists

For deciding what in the portfolio is worth licensing, the Patent Portfolio Management Toolkit supplies the inventory and the competitor mapping. For the clearance a licensee still needs, the Freedom-to-Operate and Patent Clearance Toolkit covers what a licence does not. Where the patents are declared essential to a standard, the Standard-Essential Patents and FRAND Toolkit governs the terms. Where the licence is part of a development relationship, the Technology Contracts Toolkit covers the service and data provisions that travel with it. And where negotiation fails, the Patent Litigation Toolkit is the alternative both sides are pricing against.